CoChat

Long‐term efficacy of miglustat in paediatric patients with Niemann‐Pick disease type C

Chien, Y. H., Peng, S. F., Yang, C. C., Lee, N. C., Tsai, L. K., Huang, A. C., Su, S. C., Tseng, C. C., Hwu, W. L. · 2013 · Journal of Inherited Metabolic Disease
Cited by 41

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Niemann‐Pick disease type C (NP‐C) is a rare inherited neurovisceral disease characterized by progressive neurological manifestations. Oral miglustat was first approved for the treatment of children and adults with NP‐C in Europe in 2009. There are still relatively few published data on the long‐term efficacy and safety of miglustat in patients with NP‐C in clinical practice. We report the effects of up to 6 years of treatment with miglustat 100 mg t.i.d. in five children. Overall, 3/5 patients displayed progressive dysphagia before starting miglustat, and 4/5 showed marked cognitive and/or motor impairment. The mean age at treatment start was 11.6 years, and the median (range) duration of therapy so far is 4 (4.1 to 6.1) years. No treatment dose alterations were required, but therapy was interrupted for 1–3 months at least once in all patients due to supply issues. Swallowing function was stabilised during miglustat therapy, with no significant increase in Han dysphagia scale or aspiration‐penetration index scores among four evaluable patients (p > 0.05). Scores on the mini‐mental state examination indicated an improvement in cognitive function during the first 3–6 months of miglustat therapy, followed by stabilisation up to 5 years. Ambulatory function remained stable for at least the first 2 years of treatment in most patients, but there was a trend towards deterioration thereafter, possibly related to treatment interruptions. The safety/tolerability profile of miglustat was similar to previous clinical studies, although reports of gastrointestinal disturbances were rare. Overall, miglustat appeared to stabilise key parameters of neurological disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10545-012-9479-9

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 41

Metadata

Authors
Chien, Y. H., Peng, S. F., Yang, C. C., Lee, N. C., Tsai, L. K., Huang, A. C., Su, S. C., Tseng, C. C., & Hwu, W. L.
Venue
Journal of Inherited Metabolic Disease
Publisher
Wiley
Published
2012-04-05
Volume
36
Issue
1
Pages
129-137
ISSN
  • 0141-8955 (ISSN-L)
  • 1573-2665
OpenAlex
W2043965507
Cited by
41
References
2
FWCI
3.40
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term efficacy of miglustat in paediatric patients with Niemann‐Pick disease type C. https://app.cochat.ai/papers/10.1007/s10545-012-9479-9
The paper
Chien, Y. H., Peng, S. F., Yang, C. C., Lee, N. C., Tsai, L. K., Huang, A. C., Su, S. C., Tseng, C. C., & Hwu, W. L. (2013). Long‐term efficacy of miglustat in paediatric patients with Niemann‐Pick disease type C. Journal of Inherited Metabolic Disease. https://doi.org/10.1007/s10545-012-9479-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.